Overview

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

An open label, randomized study of neoadjuvant nivolumab and chemotherapy, with or without sub-ablative stereotactic body radiation therapy, for resectable stage IIA to IIIB non-small cell lung cancer

Phase:

Phase 2

Details

Lead Sponsor:

Montefiore Medical Center

Collaborator:

Bristol-Myers Squibb

Treatments:

Cisplatin
Docetaxel
Gemcitabine
Nivolumab
Pemetrexed